Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

BMS turns to mechanistic diversity in early oncology pipeline

BMS has holes to fill with upcoming patent expirations

February 20, 2021 3:29 AM UTC

As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces and technologies to see what sticks.

Now that the dust has settled on its 2019 acquisition of Celgene Corp., Bristol Myers Squibb Co. (NYSE:BMY) has to integrate the assets into its pipeline. It also has to work the series of deals it’s made since then and the investment in internal R&D into a portfolio that will yield revenue drivers as patent expirations for its top three sellers — Revlimid lenalidomide, Eliquis apixaban and Opdivo nivolumab — begin between one and eight years from now...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Bristol Myers Squibb Co.